[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583436":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":22,"locations":29,"responsibleParty":56,"collaborators":21,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":21,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":21,"enrollmentInfo":67,"targetDuration":21,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":78,"whyStopped":21,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"patients that newly diagnosed multiple myeloma with and without renal impairment","Measurement of serum uromodulin in patients that newly diagnosed multiple myeloma with and without renal impairment and follow up these patients for 1 year.\n\n* All patients will be included within certain inclusion criteria after written consent will be subjected to;\n* Full medical history and clinical examination\n* Imaging:\n\n  * abdominal ultrasound.\n  * bone scan or low dose CT for lytic lesions.\n* Laboratory tests:\n\n  * complete blood count with blood film\n  * serum creatinine and urea and estimated GFR according to CKD-EPI\n  * urine analysis\n  * C-reactive protein (CRP)\n  * serum calcium\n  * serum total proteins and serum albumin\n  * serum uric acid\n  * 24 hours urinary protein.\n  * Urine and\\\\or protein electrophoresis with Immunofixation.\n  * Serum Free light chains\n  * Beta 2 microglobulin.\n  * LDH\n  * Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.\n* Renal biopsy if indicated.",[12],"Diagnostic Test: - Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DIAGNOSTIC_TEST","- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.","\\- Serum Uromodulin level quantitative test by ELISA technique at day 0, day 21 of 1st cycle and at the end of 2nd cycle of bortezomib based protocol of chemotherapy.",[9],[20],"• All patients will be included within certain inclusion criteria after written consent will be subjected to; • Full medical history and clinical examination • Imaging: - abdominal ultrasound. - bone",null,[23],{"name":24,"role":25,"phone":26,"phoneExt":27,"email":28},"Usra Mohamed Farrag Ahmed farrag Usra Mohamed Farrag Ahmed, assistant lecturer","CONTACT","002- 01013460518","002- 010134605","usramohamed24@gmail.com",[30],{"facility":5,"status":21,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Asyut","Eygpt","71525","Egypt","EG",{"type":37,"coordinates":38},"Point",[39,40],31.18368,27.18096,{"lat":40,"lon":39},[43,48,51,54],{"name":44,"role":25,"phone":45,"phoneExt":46,"email":47},"assuit university medicine assuit university,faculty of medicine","0882411900","01020462809","med@aun.edu.eg",{"name":49,"role":50,"phone":21,"phoneExt":21,"email":21},"Usra Mohamed Farrag Ahmed farrag Usra Mohamed Farrag Ahmed, master degree","PRINCIPAL_INVESTIGATOR",{"name":52,"role":53,"phone":21,"phoneExt":21,"email":21},"Mohsen Mohammed Hussein El Kossi hussein Mohsen Mohammed Hussein El Kossi, professor","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":21,"phoneExt":21,"email":21},"Maha Mohammed Abdel-Aziz Abdel-Aziz Maha Mohammed Abdel-Aziz, lecturer",{"type":50,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Usra Mohamed Farag","Usra Mohamed farrag Ahmed","100583436","role-of-uromodulin-in-management-of-multiple-myloma-100583436",false,"NCT06876298","Role of Uromodulin in Management of Multiple Myloma","Inclusion Criteria:\n\n* Adult patients ≥ 18 years old that newly diagnosed with multiple myeloma according to 2024 updates in diagnosis of multiple myeloma (10) with and without renal impairment at nephrology and haematology unit of internal medicine department.\n\nExclusion Criteria:\n\n* any patient have evidence of renal impairment due to any cause other than multiple myeloma as diabetic nephropathy, hypertensive nephropathy or lupus nephritis ... etc.","ALL","18 Years",{"count":68,"type":69},30,"ESTIMATED","INTERVENTIONAL",[72],"NA","• To Evaluate the role of uromodulin level in early diagnosis of cast nephropathy and to detect its prognostic value in multiple myeloma patients",[75],"Multiple Myloma",[77],"uromodulin","NOT_YET_RECRUITING","2025-03-12",{"date":81,"type":82},"2025-03-14","ACTUAL",{"date":84,"type":69},"2025-03-25",{"date":86,"type":69},"2027-03-25",{"name":5,"class":6},1]